Market Place
Sourcing Support
Addressing Nitrosamine Risks in Pharmaceutical Manufacturing
10 Oct 2024 //
PRESS RELEASE
Aptar`s N-Sorb Accepted To FDA`s Emerging Technology Program
23 Sep 2024 //
BUSINESSWIRE
Nitrosating Agent Mitigation Strategy
29 Aug 2024 //
CONTRACT PHARMA
EMA seeks feedback on revised guideline on the chemistry of active substances
01 Aug 2024 //
RAPS
N-Nitroso Duloxetine Analytical Method Published in ACS Omega
15 Mar 2024 //
PRESS RELEASE
Project Nitroso-Sitagliptin Impurity
07 Mar 2024 //
PRESS RELEASE
Fighting tuberculosis: EUROAPI’s rifampicin API meets new requirements for nitrosamine impurity standards
24 Oct 2023 //
PRESS RELEASE
N-nitrosamine Risk Assessments for Oral Dosage Forms
23 Jun 2023 //
CONTRACT PHARMA
Health Canada Issues Recall of AA Pharma`s Amitriptyline antidepressant drugs
07 Feb 2023 //
HEALTH CANADA
Merck set to remove cancer-causing chemical from top diabetes drugs
18 Jan 2023 //
REUTERS
Deciphera revives hopes for Qinlock with subgroup analysis, plots new PhIII
04 Jan 2023 //
ENDPTS
Generic drug industry pushes FDA to address nitrosamine impurities in a new way
09 Nov 2022 //
ENDPTS
Prompted by recent recalls, regulators scramble to address novel nitrosamines
31 Oct 2022 //
RAPS
FDA: Here’s Yet Another Blood Pressure Medication Recall For Cancer Concerns
30 Oct 2022 //
FORBES
Aurobindo Pharma’s US branch issues a recall of a generic medicine
26 Oct 2022 //
ENDPTS
Safe approach in delivering nitrosamine-free API products
10 Oct 2022 //
PRESS RELEASE
Pfizer Canada recalls BP drug on potential cancer-causing impurity
05 Mar 2022 //
HEALTH CANADA
Health Canada Recalls Pfizer`s Accuretic blood pressure tablets due to a nitrosamine impurity
03 Mar 2022 //
HEALTH CANADA
Pfizer yanked 15 lots of blood pressure med Inderal in Canada
03 Mar 2022 //
FIERCEPHARMA
USP’s Nitrosamine Impurity Standard is Now Official
02 Dec 2021 //
PHARMTECH
USP Standard for Nitrosamine Impurities Becomes Official
01 Dec 2021 //
PRESS RELEASE
FDA suggests alternative approaches for nitrosamine risk assessments
23 Nov 2021 //
RAPS
Pfizer recalls all stock of smoking cessation med over nitrosamine contamination
16 Oct 2021 //
PHARMACEUTICAL JOURNALS
Nitrosamine Risk Assessment Date Extended
02 Mar 2021 //
PHARMTECH
USP Proposes Analytical Methods For Drug Makers To Detect Nitrosamine Impurities
09 Sep 2020 //
PINK SHEET
Rigorous Detection of Nitrosamine Contaminants in Metformin Products
04 Sep 2020 //
FDA
Ranitidine products recalled because of a nitrosamine impurity
31 Aug 2020 //
NEWSWIRE
FDA addresses nitrosamines in TB drugs
27 Aug 2020 //
RAPS
Nitrosamines Risk Assessments for BASF’s pharmaceutical excipients
24 Aug 2020 //
PHARMAEXCIPIENTS
Biologicals Join List Of EU Medicines Requiring Nitrosamine Evaluation
13 Jul 2020 //
PHARMAINTELLIGENCE
Nitrosamines Deadline Extension
28 May 2020 //
PRESS RELEASE
FDA Alerts Patients and Health Professionals to Nitrosamine Impurity Metformin
28 May 2020 //
PRNEWSWIRE
Nitrosamine free development process
26 May 2020 //
PRESS RELEASE
Ranitidine Medicines Suspended
23 May 2020 //
PRESS RELEASE
Detecting Nitrosamine Contamination
24 Mar 2020 //
PRESS RELEASE
APIC Guidance on Nitrosamines Risk Assessment
17 Mar 2020 //
PRESS RELEASE
Nitrosamine risk evaluation
28 Feb 2020 //
PRESS RELEASE
Worried about Nitrosamine contamination?
17 Feb 2020 //
PRESS RELEASE
FDA tags Torrent as key offender in production of tainted blood pressure meds
17 Oct 2019 //
FIERCE PHARMA
EMA to provide guidance on avoiding nitrosamines in human medicines
14 Sep 2019 //
EMA
FDA expands blood pressure drug recall for fifth time this year
28 Apr 2019 //
NBCNEWS
EMA Urges Pioglitazone Manufacturers to Check for Nitrosamine Impurities
26 Apr 2019 //
RAPS
FDA provides update on its ongoing investigation into ARB drug products
01 Mar 2019 //
BIOSPACE
